title: Francisella tularensis inhibits the intrinsic and extrinsic pathways to delay constitutive apoptosis and prolong human neutrophil lifespan.
abstract: Francisella tularensis is a facultative intracellular bacterium that infects many cell types, including neutrophils. We demonstrated previously that F. tularensis inhibits NADPH oxidase assembly and activity and then escapes the phagosome to the cytosol, but effects on other aspects of neutrophil function are unknown. Neutrophils are short-lived cells that undergo constitutive apoptosis, and phagocytosis typically accelerates this process. We now demonstrate that F. tularensis significantly inhibited neutrophil apoptosis as indicated by morphologic analysis as well as annexin V and TUNEL staining. Thus, ∼80% of infected neutrophils remained viable at 48 h compared with ∼50% of control cells, and ∼40% of neutrophils that ingested opsonized zymosan. In keeping with this finding, processing and activation of procaspases-8, -9, and -3 were markedly diminished and delayed. F. tularensis also significantly impaired apoptosis triggered by Fas crosslinking. Of note, these effects were dose dependent and could be conferred by either intracellular or extracellular live bacteria, but not by formalin-killed organisms or isolated LPS and capsule, and were not affected by disruption of wbtA2 or FTT1236/FTL0708-genes required for LPS O-antigen and capsule biosynthesis. In summary, we demonstrate that F. tularensis profoundly impairs constitutive neutrophil apoptosis via effects on the intrinsic and extrinsic pathways, and thereby define a new aspect of innate immune evasion by this organism. As defects in neutrophil turnover prevent resolution of inflammation, our findings also suggest a mechanism that may in part account for the neutrophil accumulation, granuloma formation, and severe tissue damage that characterizes lethal pneumonic tularemia.
authors.affiliation: Inflammation Program, University of Iowa and the Veterans Administration Medical Center, Iowa City, IA 52242, USA.
authors.forename: Justin T
authors.initials: JT
authors.lastname: Schwartz
authors.forename: Jason H
authors.initials: JH
authors.lastname: Barker
authors.forename: Justin
authors.initials: J
authors.lastname: Kaufman
authors.forename: Drew C
authors.initials: DC
authors.lastname: Fayram
authors.forename: Jenna M
authors.initials: JM
authors.lastname: McCracken
authors.forename: Lee-Ann H
authors.initials: LA
authors.lastname: Allen
mesh_terms: D000328:Adult; D017304:Annexin A5 / Q000032:analysis; D017209:Apoptosis / Q000502:physiology*; D016667:Bacterial Capsules / Q000235:genetics / Q000276:immunology; D020169:Caspases / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D053938:DNA Fragmentation; D004789:Enzyme Activation; D005604:Francisella tularensis / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity / Q000502:physiology*; D006801:Humans; D057131:Immune Evasion / Q000276:immunology*; D020287:In Situ Nick-End Labeling; D016209:Interleukin-8 / Q000032:analysis; D008070:Lipopolysaccharides / Q000276:immunology; D009504:Neutrophils / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D009895:Opsonin Proteins / Q000276:immunology; D010587:Phagocytosis; D016897:Respiratory Burst; D014774:Virulence; D015054:Zymosan / Q000276:immunology; D019014:fas Receptor / Q000502:physiology
chemical_list: D017304:Annexin A5; C508606:CXCL8 protein, human; D015853:Cysteine Proteinase Inhibitors; D016209:Interleukin-8; D008070:Lipopolysaccharides; D009895:Opsonin Proteins; D019014:fas Receptor; D015054:Zymosan; D020169:Caspases